ConductScience.org, home

Paper6975652

Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor.

Lotze MT and 4 others. Cancer Res, 1981. Cited by 613 papers, by iCite.

Cite this record

ConductScience Library. Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor. Papers, record 6975652. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/6975652

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor.
PubMed
Journal
Cancer Res
PubMed
Year
1981
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
613
iCite
Relative citation ratio, by iCite
13.5
iCite
Revised in PubMed
2004-11-17
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Lotze MTM T
2Grimm EAE A
3Mazumder AA
4Strausser JLJ L
5Rosenberg SAS A

Source PubMed

Download CSV of authors

Topics14

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Interleukin-2Major topic
LymphokinesMajor topic
NeoplasmsMajor topic
T-LymphocytesMajor topic
Adult
Aged
Cells, Cultured
Cytotoxicity, Immunologic
Female
Humans
Male
Middle Aged
Osteosarcoma
Time Factors

Source PubMed

Download CSV of topics

Cited by134

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 613 citations.

PMIDTitleJournalYearIn PapersSource
42272961Adoptive T-cell therapies in the clinic.Bioeng Transl Med2026https://conductscience.org/library/papers/42272961PubMed
41927344Bright side of the dark genome: antigens for next-gen cancer vaccines.J Immunother Cancer2026https://conductscience.org/library/papers/41927344PubMed
41707655Cell therapy for brain tumors: The first 60 years.Cell Rep Med2026https://conductscience.org/library/papers/41707655PubMed
41006825The opportunities and barriers for developing tumour-infiltrating lymphocyte therapy for patients with advanced genitourinary cancers.Nat Rev Urol2026https://conductscience.org/library/papers/41006825PubMed
40679708Tumor infiltration therapy: from FDA approval to next-generation approaches.Clin Exp Med2025https://conductscience.org/library/papers/40679708PubMed
39126091Innate Immune Cells in Melanoma: Implications for Immunotherapy.Int J Mol Sci2024https://conductscience.org/library/papers/39126091PubMed
37827864IL-2-driven CD8+ T cell phenotypes: implications for immunotherapy.Trends Immunol2023https://conductscience.org/library/papers/37827864PubMed
36077696Tumor Infiltrating Lymphocyte (TIL) Therapy for Solid Tumor Treatment: Progressions and Challenges.Cancers (Basel)2022https://conductscience.org/library/papers/36077696PubMed
35821998Induction of T Cell Senescence by Cytokine Induced Bystander Activation.Front Aging2021https://conductscience.org/library/papers/35821998PubMed
35819272Facts and Hopes for Immunotherapy in Renal Cell Carcinoma.Clin Cancer Res2022https://conductscience.org/library/papers/35819272PubMed
35314852Harnessing natural killer cells for cancer immunotherapy: dispatching the first responders.Nat Rev Drug Discov2022https://conductscience.org/library/papers/35314852PubMed
34937915The foundations of immune checkpoint blockade and the ipilimumab approval decennial.Nat Rev Drug Discov2022https://conductscience.org/library/papers/34937915PubMed
34140957Cell Therapy With TILs: Training and Taming T Cells to Fight Cancer.Front Immunol2021https://conductscience.org/library/papers/34140957PubMed
34134616Immersion in the search for effective cancer immunotherapies.Mol Med2021https://conductscience.org/library/papers/34134616PubMed
33723260Personalized cancer vaccine strategy elicits polyfunctional T cells and demonstrates clinical benefits in ovarian cancer.NPJ Vaccines2021https://conductscience.org/library/papers/33723260PubMed
33407739NK cell-based cancer immunotherapy: from basic biology to clinical development.J Hematol Oncol2021https://conductscience.org/library/papers/33407739PubMed
32934330Exploring the NK cell platform for cancer immunotherapy.Nat Rev Clin Oncol2021https://conductscience.org/library/papers/32934330PubMed
29456568Harnessing the immune system in the battle against breast cancer.Drugs Context2018https://conductscience.org/library/papers/29456568PubMed
29443657IL-2 and Beyond in Cancer Immunotherapy.J Interferon Cytokine Res2018https://conductscience.org/library/papers/29443657PubMed
28491060Shaping of Natural Killer Cell Antitumor Activity by Ex Vivo Cultivation.Front Immunol2017https://conductscience.org/library/papers/28491060PubMed

See all 134 cited byDownload CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
IL23558PubTator's text mininghttps://conductscience.org/library/genes/3558

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/6975652

GET https://conductscience.org/api/papers/v1/6975652/cited_by?page=2